Rewarding Innovation Was the Primary Goal in 2022 Reform Debate: MHLW Official

Tetsunari Kihira, Pharmaceutical Management Director, Medical Economics Division, Health Insurance Bureau, MHLW The primary goal of drug pricing reform discussions for FY2022 was to ensure appropriate rewards for innovation, and this was achieved with newly agreed rules including the expansion...read more